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licenses/by/4.0/).Abstract Background: Up to 50% of men with poor prognosis, non-seminoma germ cell tu-
mours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An
intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met
response targets in a randomised, phase II trial (74% complete response or partial response
marker negative, 90% confidence interval (CI) 61%e85%).
Aim: To assess long-term outcomes and late toxicity associated with CBOP/BEP.
Methods: Patients with poor prognosis extracranial GCT were randomised to 4xBEP or
CBOP/BEP (2xCBOP, 2xBO, 3xBEP with 15,000iu of bleomycin). Low-dose, stabilisingancer Research UK (C1198 / A4274); additional support was provided by the Medical Research Council
12023/28) who coordinated the trial.
l Trials Unit at UCL, Institute of Clinical Trials & Methodology, 90 High Holborn 2nd Floo, London,
(F.H. Cafferty).
ed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
F.H. Cafferty et al. / European Journal of Cancer 127 (2020) 139e149140chemotherapy before entry was permitted. Response rates (primary outcome) were reported
previously. Here, we report secondary outcomes: progression-free survival (PFS), overall sur-
vival (OS) and late toxicity. Prognostic factors and the impact of marker decline are assessed
in exploratory analysis.
Results: Eighty-nine patients (43 CBOP/BEP) were randomised. After median 63 months
follow-up, 3-year PFS is 55.7% (95% CI: 39.7%, 69.0%) for CBOP/BEP and 38.7% (95%
CI: 24.7%, 52.4%) for BEP (hazard ratio [HR]: 0.59 (0.33, 1.06), p Z 0.079). Three-year OS
is 65.0% (48.8%, 77.2%) and 58.5% (43.0%, 71.2%), respectively (HR: 0.79 (0.41, 1.52),
pZ 0.49). Twelve-month toxicity was affected by subsequent treatments, with no clear differ-
ences between arms. Stabilising chemotherapy was associated with poorer PFS (HR: 2.09
(1.14, 3.81), pZ 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not.
Conclusion: Although not powered for PFS, results for CBOP/BEP are promising. Impact on
OS was less clear (and will be affected by subsequent therapy). Further study in an interna-
tional phase III trial is warranted.
Trial registration: ISRCTN 53643604.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
BEP (bleomycin, etoposide and cisplatin) chemo-
therapy has been the standard treatment for metastatic
germ cell tumours (GCTs) for many years and is suc-
cessful for many patients. However, there is a well-
characterised poor prognosis group for whom cure
rates remain less than 50% [1]. Attempts to improve on
this have, to date, been largely unsuccessful [2]. Most
recently, the GETUG (Genito-Urinary Group of the
French Federation of Cancer Centres) 13 trial sug-
gested that dose intensification based on inadequate
marker decline during early treatment may be benefi-
cial [3].
TE23 (ISRCTN 53643604) was a randomised, phase
II trial aiming to assess the efficacy and safety of a
dose-intense regimen, CBOP/BEP (carboplatin, bleo-
mycin, vincristine, cisplatin/BEP), in these patients.
The regimen, originally developed by the Royal
Marsden Testicular Tumour Unit based on Wettlaufer
et al. [4], features early dose-intensity,{super comma?}
use of infusional bleomycin (rather than bolus in-
jections) and BEP with reduced bleomycin dose in the
second stage.
In the primary analysis, CBOP/BEP met response
targets: 74% of patients achieved a complete response or
partial response marker negative (90% CI: 61%e85%;
primary outcome) [2]. The trial was not powered to
compare arms but BEP response rate e used as a
benchmark e was as expected at 61% (90% CI: 48%,
73%). Acute toxicity, particularly haematological, was
higher with CBOP/BEP.
Here, we report long-term data from the trial,
including efficacy outcomes and late toxicity. Inaddition, the role of early marker decline for predicting
long-term outcomes is considered.2. Materials and methods
2.1. Patients
Eligible patients were 16 years with extracranial GCT
and at least one International Germ Cell Cancer
Collaborative Group (IGCCCG) poor prognosis feature
(mediastinal primary, non-pulmonary visceral metasta-
ses, AFP [alpha fetaprotein] > 10,000 ng/ml, HCG
[human chorionic gonadotropin] > 50,000iu/l or LDH
[lactase dehydrogenase] > 10 upper limit of normal
[ULN]). Diagnoses were based on histology; or elevated
AFP and/or HCG in a patient with a testicular tumour;
or unequivocally elevated markers (AFP>1000 ng/ml or
HCG>5000iu/l) in men aged <45 years without a testis
tumour but with an otherwise appropriate clinical pic-
ture. Applicable regulatory and ethics approvals, and
written informed consent, were obtained.2.2. Study design
This was an open-label, parallel, phase II, multicentre,
UK trial with randomisation (1:1) to BEP or CBOP/
BEP. Eligible patients not deemed fit enough to receive
protocol treatment (by the treating investigator) could
be stabilised with low-dose chemotherapy (normally 20
mg/m2 of cisplatin 20 mg/m or carboplatin AUC3 and
etoposide or vincristine for two days) before enrolment.
Randomisation at the coordinating trial unit (accessible
by telephone to recruiting teams) used minimisation
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site, centre and a random element.
2.3. Treatment and follow-up assessments
The control arm comprised 4 cycles of Indiana-style 5-
day BEP [5] over 12 weeks: 100 mg/m2 of etoposide and
20 mg/m2 of cisplatin on days 1e5 of each cycle and 12
doses of 30,000iu of bleomycin weekly. The CBOP/
BEP arm comprised 6 chemotherapy cycles over 15
weeks. At weeks 1 and 3, 50 mg/m2 of cisplatin on days
1 and 2 and 2 mg of vincristine and 15000iu of bleo-
mycin on day 1 were administered. At weeks 2 and 4,
40 mg/m2 of cisplatin, 2 mg of vincristine and carbo-
platin AUC3 all on day 1 and 15000iu of bleomycin by
24-h iv infusion on days 1e5 (total dose 75000iu) were
administered. At weeks 5 and 6, 2 mg of vincristine and
15000iu of bleomycin on day 1 were administered. At
weeks 7e15, 3 cycles of Indiana-style BEP adminis-
tered as for the control arm, except with modified
bleomycin dose of 15000iu weekly. Prophylactic gran-
ulocyte-colony stimulating factor (G-CSF) was
mandated (in week five of CBOP/BEP and during each
BEP cycle in both arms) from January 2008 following
an Independent Data Monitoring Committee
recommendation.
Assessments and management during treatment
have been reported previously [2]. The protocol speci-
fied a 5-year follow-up period after randomisation.
Follow-up assessments (clinical examination, chest x-
ray and markers) were performed two-monthly in year
one, 3-monthly in year two and then six months once to
5 years. Audiometry and lung function were assessed at
12 months and semen analysis at 24 months. Cross-
sectional imaging was performed at 2e4 weeks after
end of treatment. It was additionally performed to
follow residual disease 6-monthly until resolution
(<1cm), resected or stable for 1 year; 2 months after
surgical resection of tumour masses; and at the inves-
tigator’s discretion. Surgical resection was advised for
all non-resolving masses >1 cm. Management of dis-
ease progression was at the clinician’s discretion. This
analysis was planned when all of the follow-up was
complete. For patients who were lost to follow-up,
survival status was sought via general practitioners
(GPs).
2.4. Outcome measures
The primary outcome (reported previously) was
favourable response rate: the proportion of patients
achieving complete response (disappearance of all dis-
ease and normal tumour markers) or partial response
(residual mass unresected) with negative markers.
The current analysis focuses on secondary outcomes:
progression-free survival (PFS, time fromrandomisation until disease progression, relapse or
death, with treatment failure considered to be an event,
and censoring at the most recent assessment for event-
free patients); overall survival (OS, time from random-
isation until death from any cause, with censoring at the
date last known to be alive) and toxicity (Common
Terminology Criteria for Adverse Events (CTCAE)
v3.0) at 12 months (þ/ 2 months). Data on pulmonary
and audiometry investigations performed at this time
were insufficient.
2.5. Statistical analysis
PFS/OS analyses were based on Kaplan-Meier curves
and hazard ratios (HRs) derived from Cox regression
models with 95% confidence intervals (CIs). Exploratory
analyses considered the impact of IGCCCG poor risk
features [1], receipt of stabilising chemotherapy and
early marker decline, with p < 0.1 (2-sided) regarded as
significant. Marker decline was classified based on the
GETUG13 algorithm [3,6], considering AFP and HCG
values after one BEP cycle (approximately day 21) in the
BEP arm or after two CBOP cycles (approximately day
28; with day 14 values used if the later value was not
available) in the CBOP/BEP arm (appendix A).
In multivariable models, treatment effect was
adjusted for any factors with p < 0.1 in univariate
models. Power was limited, particularly for OS, where
number of events was small. All randomized patients
were included on an intent-to-treat basis with the
exception of models incorporating early marker decline,
where 3 patients who stopped treatment before the
relevant marker assessment were excluded. Subgroup
analyses considered the impact of early marker decline
in the BEP arm and in those who did not receive sta-
bilising chemotherapy.
Late toxicity data are tabulated by treatment arm for
surviving patients (regardless of subsequent treatments)
with no formal comparative tests.
Analyses were performed using Stata (StataCorp),
version 14.
3. Results
Between June 2005 and December 2009, 89 patients were
enrolled from 16 UK centres (recruiting between 1 and 15
patients each, median 5); 43 of them were randomised to
CBOP/BEP (Fig. 1). The mean age was 30 years (range
16e68), and 18 patients (20%) had mediastinal primary
tumours. Fifty-three patients (60%) had diagnosis
confirmed histologically and 36 (40%) based on markers/
clinical picture. Sixty-four patients (72%) had not un-
dergone orchidectomy at the time of trial registration.
Twenty-four patients (27%) had low-dose chemotherapy
for stabilisation. IGCCCG poor prognosis features and
receipt of stabilising chemotherapy were similar between
Fig. 1. Flow of participants through the trial. a 2 of these patients had already had a progression event at the time of loss to follow-up (1
BEP and 1 CBOP/BEP, with 38 and 9 month postprogression follow-up, respectively) and so contribute complete data to the PFS analysis;
in addition, survival information at 5 years was obtained from GPs for the 2 patients who had already progressed and a further 1 BEP
patient. b 3 patients (2 BEP, 1 CBOP/BEP) are excluded from models incorporating marker decline because they only received one cycle of
treatment in the trial and, therefore, did not have the relevant marker assessment for calculation of time to normalisation. In addition,
analyses of 12-month toxicity are restricted to surviving patients (33 BEP, 32 CBOP/BEP) with follow-up assessment data between 10 and
14 months after randomisation.
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have been reported previously: completion rates were
similarly high in the two arms (41/46, 89% for BEP; 40/
43, 93% CBOP/BEP); rates of CTCAE grade 3 symp-
toms were higher with CBOP/BEP (95% vs 63% with
BEP), largely because of haematological toxicity.
Median follow-up was 63 months e similar between
arms. All surviving patients had a minimum 58-monthfollow-up, with the exception of 6 who were lost to
follow-up (4 BEP, 2 CBOP/BEP). Of these, 2 had had
progression events (1 BEP treatment failure, with 38-
month post-failure follow-up; 1 progression following
CBOP/BEP, with 9 months follow-up thereafter). Sur-
vival status at 5 years was obtained through GPs for
these 2 patients, and for a furtherBEP patient who was
lost to follow-up.
Table 1
Baseline characteristics.
Baseline data BEP
(n Z 46)
CBOP/BEP
(n Z 43)
Overall
(n Z 89)
No. (%) No. (%) No. (%)
Age (years) Mean (range) 31 (16e68) 28 (16e60) 30 (16e68)
Site of primary tumour Testis 34 (72) 32 (74) 66 (74)
Mediastinum 9 (20) 9 (21) 18 (20)
Retroperitoneum 2 (4) 2 (5) 4 (4)
Uncleara 1 (4) 0 (0) 1 (1)
IGCCCG poor risk factors Raised markersb only 14 (30) 10 (23) 24 (27)
Mediastinal primary only 7 (15) 4 (9) 11 (12)
Non-pulmonary visceral
metastases (NPVM) only
9 (20) 10 (23) 19 (21)
Raised markers and
mediastinal primary
2 (4) 3 (7) 5 (6)
Raised markers and NPVM 14 (30) 14 (33) 28 (31)
Mediastinal primary and NPVM 0 (0) 2 (5) 2 (2)
Orchidectomy before registration No 34 (74) 30 (70) 64 (72)
Yes 12 (26) 13 (30) 25 (28)
Receipt of stabilising chemotherapy
before protocol treatment
No 33 (72) 32 (74) 65 (73)
Yes 13 (28) 11 (26) 24 (27)
CBOP/BEP, carboplatin, bleomycin, vincristine, cisplatin/BEP; BEP, bleomycin, etoposide and cisplatin; LDH, lactase dehydrogenase; AFP, alpha
fetaprotein; HCG, human chorionic gonadotropin.
a Difficult to determine between the testis and retroperitoneum.
b AFP>10,000iu/l, HCG>50,000iu/l or LDH>10  upper limit of normal.
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Time to normalisation could not be calculated for 3
patients (2 BEP, 1 CBOP/BEP) who only received one
cycle of treatment in the trial and so did not have the
relevant marker assessment. Sixty of eighty-six (70%) of
patients had unfavourable marker decline, and this was
similar in the two arms (BEP: 31/44, 70.5%, 90% CI:
57.2%e81.6%; CBOP/BEP: 29/42, 69.0%, 90% CI
55:.4%e80.6%). As might be expected, high baseline
AFP or HCG was correlated with unfavourable marker
decline. The reverse trend was seen for LDH e a small
number of patients had high (>10 ULN) LDH values,
and these patients were more likely to have favourable
marker decline. There were no other associations be-
tween IGCCCG factors or receipt of stabilising
chemotherapy and marker decline (appendix B).
3.2. PFS and OS
There were 48 PFS events (29 BEP, 19 CBOP/BEP), and
median PFS was 30 months (6 months in the BEP arm,
not yet reached in the CBOP/BEP arm). Estimated 3-
year PFS was 38.7% (95% CI: 24.7%e52.4%) in the BEP
arm and 55.7% (39.7%e69.0%) for the CBOP/BEP arm;
hazard ratio (HR) Z 0.59 (0.33e1.06), p Z 0.079 (Fig.
2a). Rates remained the same at 5 years.
There were 37 deaths (21 BEP, 16 CBOP/BEP).
Median survival time was just less than 6 years in the
BEP arm and had not yet been reached for the CBOP/
BEP arm. Estimated 3-year OS was 58.5% (43.0%e71.2%) in the BEP arm and 65.0% (48.8%e77.2%) for
the CBOP/BEP arm; HRZ 0.79 (95% CI: 0.41 to 1.52),
p Z 0.49 (Fig. 2b).
3.3. Prognostic models
Estimated 3-year PFS was higher in the group with
unfavourable marker decline compared with those with
favourable decline, though this trend was non-significant
(51.7% vs 41.0%, HR Z 0.82, p Z 0.54). Results were
similar in the subgroup who did not receive stabilising
chemotherapy and in the subgroup of BEP patients.
In univariate models, receipt of stabilising chemo-
therapy was associated with poorer PFS (Table 2). No
significant associations were observed for IGCCCG
poor risk factors, although there were non-significant
negative trends associated with mediastinal primary
site and multiple IGCCCG poor prognosis features.
Treatment effect remained similar after adjustment for
stabilising chemotherapy (Table 2).
Estimated 3-year OS was higher in the group with
unfavourable marker decline compared with those with
favourable decline, although this was non-significant
because of the low power of the model (66.7% vs 57.7%,
HR Z 0.59, p Z 0.14). Results were similar in the two
subgroup analyses.
Results for univariate and multivariable models for OS
were similar to those for PFS e the only significant asso-
ciations were for receipt of stabilising chemotherapy and
mediastinal primary tumours (appendix C). Treatment
effect remained similar after adjustment for these factors.
Fig. 2. (a) Progression-free survival according to treatment allocation; (b) Overall survival according to treatment allocation.
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At 12 months, there were 65 surviving patients (33 BEP,
32 CBOP/BEP), of which 11 (7 BEP, 4 CBOP/BEP) had
active disease. Burden of toxicity was similarly low inboth arms (Table 3). CTCAE grade 3 symptoms were
reported in five patients in the BEP arm, all of whom
had recently undergone further subsequent chemo-
therapy, and so symptoms may have been related to that
treatment (or to active disease).
Table 2
Univariate and multivariable models for predicting progression-free survival.
Factor No. Univariate HR (95% CI) e Cox model P-
value
Multivariable HR (95% CI) P-
value
Trial arm BEP 46 Ref 0.079 Ref 0.074
CBOP/BEP 43 0.59 (0.33, 1.06) 0.59 (0.33, 1.05)
AFP 10000 ng/ml 65 Ref 0.17 e e
>10000ng/ml 24 0.62 (0.31, 1.24)
HCG 50000 iu/l 58 Ref 0.40 e e
>50000 iu/l 31 1.28 (0.72, 2.31)
LDH 10xULN 80 Ref 0.63 e e
>10xULN 9 1.24 (0.52, 2.91)
IGCCCG poor prognosis markers No 32 Ref 0.48 e e
Yesa 57 0.81 (0.46, 1.45)
Mediastinal primary site No 71 Ref 0.39 e e
Yes 18 1.34 (0.68, 2.64)
Non-pulmonary visceral mets No 40 Ref 0.42 e e
Yes 49 1.27 (0.71, 2.26)
Multiple IGCCCG poor prognosis factors No 52 Ref 0.20 e e
Yesb 37 1.45 (0.82, 2.55)
Preprotocol chemotherapy No 65 Ref 0.018 Ref 0.017
Yes 24 2.07 (1.13, 3.77) 2.09 (1.14, 3.81)
Early marker decline Favourable 26 Ref 0.54 e e
Unfavourable 60 0.82 (0.44, 1.53)
LDH, lactase dehydrogenase; AFP, alpha fetaprotein; HCG, human chorionic gonadotropin; CI, confidence interval; HR, hazard ratio; CBOP/
BEP, carboplatin, bleomycin, vincristine, cisplatin/BEP; BEP, bleomycin, etoposide and cisplatin; ULN, upper limit of normal.
a One or more of: AFP>10000 ng/ml, HCG>50,000iu/l or LDH>10xULN.
b Two or more of: mediastinal primary; non-pulmonary visceral mets; AFP>10000 ng/ml; HCG>50,000iu/l; LDH>10xULN.
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Thirty-five patients relapsed or their disease progressed
during the trial (22 BEP, 13 CBOP/BEP), including all
patients with a treatment failure. Thirty patients (20
BEP, 10 CBOP/BEP) received treatment for relapse. Of
the remaining five, three died around the time of diag-
nosis of relapse/progression; one was felt not to be fit
enough for salvage treatment and died two months later;
and the remaining patient did not require further
treatment and remained alive at the end of the follow-
up. Of those treated, all but 5 received combination
chemotherapy (sometimes alongside radiotherapy or
surgery), most commonly paclitaxel, ifosfamide and
cisplatin (TIP) (13 patients), but a range of other regi-
mens were used. Only 1 patient (BEP arm) had a com-
plete response and 9 (7 BEP, 2 CBOP/BEP) had a partial
response with negative markers.
4. Discussion
Long-term data from this randomised, phase II trial
support the conclusion of the primary analysis, which
demonstrated that CBOP/BEP met response targets and
was feasible to deliver across UK centres. Although the
trial was not powered to compare efficacy outcomes, a
trend suggesting a PFS benefit was observed (3-year PFS
56% vs 39% on BEP, HR Z 0.59, p Z 0.079). Survival
rates in the two arms were more similar, althoughslightly higher with CBOP/BEP. This is to be expected
given that survival rates will be influenced by subsequent
treatment. Twice as many patients received salvage
treatment after BEP (20/46, 44%, vs 10/43, 23%, after
CBOP/BEP). This phenomenon of fewer patients in the
dose-intense arm was also seen in the GETUG13 trial
[3]. Alhough numbers are small and differences are not
statistically significant, a higher proportion of patients
achieved a favourable response to salvage chemotherapy
(BEP: 8/20, 40%; CBOP/BEP: 2/10, 20%) which will
contribute to a smaller difference between arms in OS
when compared with PFS. However, the burden of
salvage therapy, both physical and psychological, may
add to the justification for more intensive upfront ap-
proaches. In the primary analysis of TE23, CBOP/BEP
was associated with an increase in acute haematological
toxicity, but current data provide reassurance that there
are no late effects.
Our previous systematic review highlighted that e
despite a number of phase II and III randomised trials
of first-line treatment for intermediate and poor prog-
nosis of GCTs conducted internationally in recent years
e no single approach has emerged as clearly superior to
BEP [2]. A notable exception is the GETUG13 trial,
which demonstrated a PFS benefit in a subgroup of poor
risk patients with inadequate early marker decline who
were switched to a dose-dense regimen [3]. Three-year
PFS was similar to that observed with CBOP/BEP (59%
vs 48% on BEP, p Z 0.05) and e as for CBOP/BEP e
Table 3
Toxicity reported at 12 months (þ/ 2 months) after randomisation.
BEP
(n Z 33)
CBOP/BEP
(n Z 32)
CTCAE (v3.0) grade No. (%) No. (%)
Status Alive no disease 7 (21) 13 (41)
Alive inactive disease 19 (58) 15 (47)
Alive active disease 7 (21) 4 (13)
Dermatological symptoms 0 29 (88) 29 (91)
1 0 (0) 2 (6)
2 1 (3) 0 (0)
Missing 3 (9) 1 (3)
Haematological toxicity 0 28 (85) 29 (91)
1 1 (3) 1 (3)
2 0 (0) 1 (3)
3 0 (0) 0 (0)
4 1 (3) 0 (0)
Specific (grade 4) Hb 5.9
Missing 3 (10) 0 (0)
Pulmonary symptoms 0 26 (79) 30 (94)
1 1 (3) 1 (3)
2 2 (6) 0 (0)
3 1 (3) 0 (0)
Specific (grade 3) Shortness of breath
Missing 3 (9) 1 (3)
Fatigue 0 23 (70) 25 (78)
1 6 (18) 4 (13)
2 0 (0) 2 (6)
3 1 (3) 0 (0)
Missing 3 (9) 1 (3)
Cardiovascular symptoms 0 30 (91) 31 (97)
Missing 3 (9) 1 (3)
Vascular symptoms 0 30 (91) 30 (94)
1 0 (0) 1 (3)
Missing 3 (9) 1 (3)
Renal impairment 0 29 (88) 31 (97)
1 0 (0) 0 (0)
2 1 (3) 0 (0)
Missing 3 (9) 1 (3)
Anorexia/Weight loss 0 27 (82) 30 (94)
1 1 (3) 0 (0)
2 1 (3) 1 (3)
Missing 4 (12) 1 (3)
Sensory neuropathy 0 23 (70) 19 (59)
1 3 (9) 9 (28)
2 3 (9) 3 (9)
3 0 (0) 0 (0)
4 1 (3) 0 (0)
Missing 3 (9) 1 (3)
Auditory changes/tinnitus symptoms 0 27 (82) 24 (75)
1 1 (3) 5 (16)
2 1 (3) 2 (6)
3 1 (3) 0 (0)
Missing 3 (9) 1 (3)
Other symptoms 0 25 (76) 30 (94)
1 3 (9) 1 (3)
2 1 (3) 0 (0)
3 1 (3) 0 (0)
Specific (grade 3) Lumbar pain
Missing 3 (9) 1 (3)
CBOP/BEP, carboplatin, bleomycin, vincristine, cisplatin/BEP; BEP, bleomycin, etoposide and cisplatin.
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VIP (cisplatin, etoposide and ifosfamide) in
EORTC30974, although non-significant, were also
similar (2-year failure-free survival 58% vs 45%) [7] e
but other high-dose chemotherapy regimens have shown
less promise [8e10].No improvement in response rates
was seen with TIP (paclitaxel, ifosfamide and cisplatin)
when compared with BEP in a recent randomised phase
II trial (76% vs 73%; 1-year PFS 72% both arms) [11].
CBOP/BEP takes a different approach to other
treatments by delivering intensification upfront. An
advantage of this approach is that maximal therapy is
delivered when the cancer is at its most bulky, enabling a
more rapid control of symptoms and potentially also
reducing the development of resistance. Additional
benefits, from a patient perspective, are that the regimen
may be modified to fit the individual’s clinical situation
and the intensive phase is given when patients are often
in hospital with disease-related morbidity. One difficulty
is that it does not fit well with the approach of picking
patients for intensive treatment based on marker
decline. A further dose-intense approach, demonstrating
potential in early phase, single arm studies, is acceler-
ated BEP [12,13], and results from the phase III
ANZUP 1302 trial (NCT02582697) are eagerly awaited
[14]. For all of these strategies, possible risks of
increased toxicity must be carefully weighed against
potential benefits, and more long-term data are needed
to provide holistic assessments.
A factor in the lack of success of some previous trials
is that recruitment potential does not match the need. It
is also important to be realistic about what benefits are
achievable, particularly in terms of survival, which will
be influenced by subsequent treatment and events. Some
previous studies have been underpowered to detect
realistic effects or have failed to recruit to target.
Accrual to TE23 e across 16 UK centres e took twice
as long as originally anticipated (4 years rather than 2
years), hence not meeting the criteria for immediate
progression to a phase III study. Clearly, major inter-
national collaborations will be required to recruit to
well-powered phase III trials in a timely manner. In
addition, future trials in this patient group should look
to novel methodology for evaluating treatments for
rarer cancers, particularly given that there are a number
of treatment strategies which might benefit from simul-
taneous evaluation [15].
Another factor in evaluating treatment strategies is
patient selection. For many years, IGCCCG criteria
have provided a simple system e based on a large, in-
ternational data set e for identifying patients for whom
standard BEP treatment is less likely to be successful [1],
and trials have focused on these groups. However, this
classification is now based on data from several decades
ago. In the current analysis, as in other studies, there is
the suggestion of heterogeneity within the poor risk
group and a need to identify a ‘poor poor risk’ group.As part of an international effort to update the classi-
fication system, Gillessen et al. [16] have recently pro-
posed the use of age and lung metastases as additional
factors based on a large, international, pooled data set.
If validated in an independent data set (work which is
currently underway), this will facilitate more targeted
treatment approaches.
The TE23 cohort included a high proportion (40%) of
men diagnosed on the basis of markers/clinical picture,
rather than histology, and a substantial number of pa-
tients (27%) were deemed to require stabilising chemo-
therapy before full-dose treatment. As such, they may
represent a particularly poor risk group, and this is re-
flected in poorer outcomes for BEP (5-year PFS and OS:
39% and 56%, respectively) relative to contemporary
series, including the pooled data set mentioned previ-
ously [16e18]. Outcomes with CBOP/BEP (5-year PFS
and OS 56% and 63% respectively) were more similar to
these series, with improved PFS and OS relative to the
original IGCCCG study (published in 1997). As in the
other contemporary studies, even for the BEP arm of
TE23, an improvement in OS was seen relative to this
earlier study, suggesting an impact of better salvage
treatment.
In TE23, use of stabilising chemotherapy was the
factor most clearly associated with poor outcomes. The
most likely explanation for this is that the clinician’s
assessment of disease at the outset e which may not be
fully captured with current risk factors e may provide
the best indicator of the likely success of treatment.
However, we can not exclude a detrimental impact of
the use of initial low-dose therapy/delay in commencing
full-dose therapy.
Targeting more intensive treatment at those patients
most likely to benefit is desirable. One strategy is to
select patients based on marker decline after a single
BEP cycle. Within the IGCCCG poor risk group,
inadequate marker decline has been shown to be inde-
pendently associated with worse PFS and OS [6] and, in
a subsequent trial (GETUG13), this group benefitted
from switching to a dose-dense regimen [3]. In TE23,
however, inadequate marker decline was not associated
with outcomes. It is possible that early marker decline
could be less relevant in patients treated with CBOP/
BEP e however, the BEP subgroup analysis produced
similar results. This lack of association could be due to
the modest size of this study or may suggest that the
predictive value of early marker decline is less valuable
in a patient population with very poor prognostic dis-
ease. Further larger studies exploring this heterogeneity
would be helpful to establish in which patients’ marker
decline is most/least relevant.
A limitation of this study is the small sample size,
which is insufficient for complex multivariable model-
ling. The lack of a clear effect of early marker decline
may reflect this e although it is notable that no trend
was present. A further limitation is that outcome data
F.H. Cafferty et al. / European Journal of Cancer 127 (2020) 139e149148beyond 5 years were not collected, although it is notable
that few events (either PFS or OS) occurred after 3
years. A strength of this study is the randomised nature,
providing a contemporary group of patients treated with
BEP, and largely complete follow-up data up to 5 years.
5. Conclusion
CBOP/BEP has shown promise for treating men with
poor prognosis GCT in a randomised, phase II trial e
response targets were met, and a PFS benefit is sug-
gested. Impact on survival is less clear and will be
influenced by subsequent treatment. The regimen war-
rants study in a phase III trial.
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